

Cambricon (688256.SS)

China AI demand and localization trend to drive growth ahead; TP up to Rmb1,841; Buy

688256.SS 12m Price Target: **Rmb1,841.00** Price: **Rmb1,035.00** Upside: **77.9%**

We are positive on Cambricon and see strong China AI chips demand (read more: [CHIPS IV: China Semis self-sufficiency builds](#)) supporting the company's growth ahead. Cambricon's AI chips are expanding to various industries, along with continuous specification upgrades driving the blended ASP. We raise Cambricon's EBITDA by 1% / 41% / 69% / 71% / 82% in 2026-30E mainly on higher revenues, reflecting the strong China AI chips demand along with the nation's commitments toward self-sufficiency. Our TP is raised from Rmb1,614.77 to Rmb1,841 (implied 82x 2027E PE vs. +111% avg. EPS YoY in 2027-28E). Maintain Buy.

AI chips in various verticals: Cambricon enables enterprise clients across multiple sectors to deploy AI applications. Its customer base spans foundation model providers, server suppliers, AI software suppliers, cloud, energy, education, financial institutions, telecom operators, hospitals, and internet companies. For financial institutions, Cambricon's AI chips are used in business operation optimization and service efficiency improvement; for internet companies, its chips are tailored for foundation models, multimodal AI applications, search and recommendation. Its AI chips adapt to mainstream AI applications and realize scale training in 1H26. In areas including smart grids, smart mines, smart cities, and smart supermarkets, customers use Cambricon's AI chips to deploy intelligent analytics applications: (1) smart cities: intelligent semantic search and video structured analysis, (2) smart mines: cargo visual intelligent inspection, intelligent operation and maintenance of power equipment, safety production monitoring, (3) smart transportation: traffic incident detection. In 1H26, Cambricon further expanded to the supermarket / retail industry, empowering clients to adopt AI, such as customer traffic counting and recognition, smart inspection, store anti-theft and loss prevention.

AI chips migration with rising R&D engineers: On AI chips, Cambricon's next-generation intelligent processor

BUY

Verena Jeng

+852-2978-1681 | verena.jeng@gs.com
Goldman Sachs (Asia) L.L.C.

Allen Chang

+852-2978-2930 | allen.k.chang@gs.com
Goldman Sachs (Asia) L.L.C.

Yifan Hu

+852-2978-0996 | yifan.hu@gs.com
Goldman Sachs (Asia) L.L.C.


Key Data

Market cap: Rmb601.9bn / \$89.6bn
Enterprise value: Rmb599.1bn / \$89.1bn
3m ADTV: Rmb17.7bn / \$2.6bn
China
Greater China Technology
M&A Rank: 3
Leases incl. in net debt & EV?: No

GS Forecast

	12/25	12/26E	12/27E	12/28E
Revenue (Rmb mn) New	6,497.2	23,980.4	91,261.6	172,469.6
Revenue (Rmb mn) Old	6,497.2	23,661.8	39,106.5	62,158.3
EBITDA (Rmb mn)	2,185.3	6,744.1	16,004.0	31,225.8
EPS (Rmb) New	4.90	10.63	22.58	43.40
EPS (Rmb) Old	3.29	9.78	15.90	25.45
P/E (X)	125.2	97.4	45.8	23.9
P/B (X)	21.6	26.4	16.4	9.6
Dividend yield (%)	0.2	0.3	0.7	1.3
CROCI (%)	28.2	42.6	63.9	73.4
	6/26	9/26E	12/26E	3/27E
EPS (Rmb)	2.06	2.81	3.34	3.51

GS Factor Profile



Source: Company data, Goldman Sachs Research estimates.
See disclosures for details.

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

BUY

Cambricon (688256.SS)

Rating since Apr 22, 2025

Ratios & Valuation

	12/25	12/26E	12/27E	12/28E
P/E (X)	125.2	97.4	45.8	23.9
P/B (X)	21.6	26.4	16.4	9.6
FCF yield (%)	(0.4)	0.4	1.7	2.8
EV/EBITDAR (X)	117.5	88.8	40.2	20.0
EV/EBITDA (excl. leases) (X)	117.5	88.8	40.2	20.0
CROCI (%)	28.2	42.6	63.9	73.4
ROE (%)	23.9	43.9	67.1	76.4
Net debt/equity (%)	(8.0)	(17.3)	(45.4)	(56.4)
Net debt/equity (excl. leases) (%)	(8.0)	(17.3)	(45.4)	(56.4)
Interest cover (X)	929.4	166.8	8,384.6	16,522.2
Days inventory outst, sales	188.7	102.2	49.0	44.5
Receivable days	27.7	10.3	3.0	2.0
Days payable outstanding	80.1	30.0	30.0	30.0
DuPont ROE (%)	17.4	37.8	54.5	60.4
Turnover (X)	0.5	1.2	2.5	2.8
Leverage (X)	1.1	1.2	1.4	1.4
Gross cash invested (ex cash) (Rmb)	12,925.9	17,735.3	27,959.6	47,182.8
Average capital employed (Rmb)	7,228.1	12,198.2	13,906.7	16,997.8
BVPS (Rmb)	28.41	39.18	62.94	108.29

Growth & Margins (%)

	12/25	12/26E	12/27E	12/28E
Total revenue growth	453.2	269.1	280.6	89.0
EBITDA growth	445.6	208.6	137.3	95.1
EPS growth	551.8	116.6	112.5	92.2
DPS growth	NM	116.6	112.5	92.2
EBIT margin	29.9	26.8	17.2	17.9
EBITDA margin	33.6	28.1	17.5	18.1
Net income margin	31.7	25.8	15.7	15.8

Price Performance

Source: FactSet. Price as of 21 Aug 2026 close.

Income Statement (Rmb mn)

	12/25	12/26E	12/27E	12/28E
Total revenue	6,497.2	23,980.4	91,261.6	172,469.6
Cost of goods sold	(2,913.9)	(11,674.5)	(44,716.5)	(85,370.3)
SG&A	(266.1)	(266.7)	(293.3)	(322.7)
R&D	(1,350.8)	(5,468.5)	(30,116.3)	(55,190.3)
Other operating inc./exp.)	(25.8)	(146.8)	(456.3)	(689.9)
EBITDA	2,185.3	6,744.1	16,004.0	31,225.8
Depreciation & amortization	(244.8)	(320.1)	(324.9)	(329.3)
EBIT	1,940.6	6,424.1	15,679.1	30,896.5
Net interest inc./exp.)	11.1	(30.6)	9.5	10.1
Income/(loss) from associates	8.9	83.3	67.3	—
Pre-tax profit	2,059.4	6,374.5	15,863.3	30,986.5
Provision for taxes	(0.9)	(194.1)	(1,576.9)	(3,718.4)
Minority interest	0.7	(1.3)	(2.9)	(2.9)
Preferred dividends	—	—	—	—
Net inc. (pre-exceptionals)	2,059.2	6,179.0	14,283.6	27,265.3
Post-tax exceptionals	—	—	—	—
Net inc. (post-exceptionals)	2,059.2	6,179.0	14,283.6	27,265.3
EPS (basic, pre-exception) (Rmb)	4.90	10.63	22.58	43.40
EPS (diluted, pre-exception) (Rmb)	4.90	10.63	22.58	43.40
EPS (basic, post-exception) (Rmb)	4.90	10.63	22.58	43.40
EPS (diluted, post-exception) (Rmb)	4.90	10.63	22.58	43.40
DPS (Rmb)	1.51	3.26	6.94	13.33
Div. payout ratio (%)	30.7	30.7	30.7	30.7

Balance Sheet (Rmb mn)

	12/25	12/26E	12/27E	12/28E
Cash & cash equivalents	1,317.4	2,845.8	11,939.0	25,456.8
Accounts receivable	670.6	682.8	817.4	1,072.7
Inventory	4,943.5	8,490.1	16,012.1	26,088.3
Other current assets	5,148.9	5,149.1	5,149.2	5,149.2
Total current assets	12,080.4	17,167.8	33,917.6	57,767.0
Net PP&E	372.7	1,099.9	1,802.0	2,495.0
Net intangibles	189.1	168.3	147.4	126.5
Total investments	299.7	299.7	299.7	299.7
Other long-term assets	495.8	495.8	495.8	495.8
Total assets	13,437.7	19,231.5	36,662.6	61,184.0
Accounts payable	765.0	1,154.1	6,196.6	7,836.9
Short-term debt	366.8	17.0	17.0	17.0
Short-term lease liabilities	—	—	—	—
Other current liabilities	201.2	1,466.5	3,955.8	7,943.0
Total current liabilities	1,333.0	2,637.6	10,169.3	15,796.9
Long-term debt	—	—	—	—
Long-term lease liabilities	—	—	—	—
Other long-term liabilities	261.5	261.5	261.5	261.5
Total long-term liabilities	261.5	261.5	261.5	261.5
Total liabilities	1,594.5	2,899.1	10,430.8	16,058.4
Preferred shares	—	—	—	—
Total common equity	11,836.2	16,324.0	26,220.5	45,111.4
Minority interest	7.1	8.4	11.3	14.2
Total liabilities & equity	13,437.7	19,231.5	36,662.6	61,184.0
Net debt, adjusted	(950.5)	(2,828.8)	(11,922.0)	(25,439.8)

Cash Flow (Rmb mn)

	12/25	12/26E	12/27E	12/28E
Net income	2,059.2	6,179.0	14,283.6	27,265.3
D&A add-back	244.8	320.1	324.9	329.3
Minority interest add-back	(0.7)	1.3	2.9	2.9
Net (inc)/dec working capital	(3,275.8)	(3,169.7)	(2,614.1)	(8,691.2)
Other operating cash flow	474.2	(0.2)	(0.1)	—
Cash flow from operations	(498.4)	3,330.5	11,997.1	18,906.3
Capital expenditures	(568.7)	(887.3)	(867.0)	(862.3)
Acquisitions	(3,554.1)	—	—	—
Divestitures	—	—	—	—
Others	(407.5)	(139.2)	(139.1)	(139.0)
Cash flow from investing	(4,530.3)	(1,026.5)	(1,006.1)	(1,001.3)
Repayment of lease liabilities	—	—	—	—
Dividends paid (common & pref)	(4.1)	(632.5)	(1,897.8)	(4,387.1)
Inc/(dec) in debt	247.3	(349.8)	—	—
Other financing cash flows	4,112.3	(425.9)	(1,897.8)	(4,387.1)
Cash flow from financing	4,359.6	(775.7)	(1,897.8)	(4,387.1)
Total cash flow	(669.1)	1,528.4	9,093.2	13,517.8
Free cash flow	(1,067.1)	2,443.3	11,130.2	18,043.9

Source: Company data, Goldman Sachs Research estimates.

microarchitecture and instruction set are under development, aiming at optimizing scenarios such as training and inference for natural language processing foundation models, video and image generation foundation models, and vertical foundation models, enhancing programming flexibility, ease of use, performance, power consumption, and chips size. The company continues to focus on stronger computing power, memory capacity and bandwidth, enhancing the adaptability in various AI training and inferencing tasks. Cambricon's AI chips completed adaptation for mainstream local foundation models, including GLM, DeepSeek, Qwen, Kimi, and MiniMax. Cambricon was added to the US Entity list in Dec 2022, and suffered from a talent loss in 2023. While the number of R&D engineers troughed in 1H24 at 727 people, it has risen back to 1,007 people in 1H26, which should support the company's future growth.

Strong 3Q26 ahead: 2Q26 revenues were up 8% QoQ, slower than the +53% QoQ in 1Q26. We attribute it to clients' procurement pace and wafer supply. Historically, the slow increase in inventory is usually followed by a slow revenue QoQ in the next quarter. The company's inventory was down 9% QoQ in 1Q26 (vs. revenues +8% QoQ in 2Q26), while the inventory strongly increased 83% QoQ in 2Q26, and mainly contributed by raw materials (mainly wafer), suggesting a strong growth in revenue QoQ in 3Q26. The strong raw material increase (+779% YoY in 1H26) also reflects local foundries' development of advanced nodes, supporting the nation's development in generative AI.

Earnings revision: We raised EBITDA by 1% / 41% / 69% / 71% / 82% in 2026-30E mainly on higher revenues, reflecting strong AI demand in China and the nation's commitments on localization. We expect Cambricon's continuous AI chips specification upgrade to drive its ASP increase in the coming years. We reduce GM considering the expansion in China CSPs, who have strong bargaining power, and an industry practice of lowering ASP when undergoing large scale procurement. We also raise R&D to support Cambricon's AI chip development which spans across AI chip design, hardware development based on the AI chips (e.g. GPU module, baseboard, motherboard, server), and base software (e.g. AI application development platform, and toolkits).

Exhibit 1: Cambricon earnings revision

Rmb m	2026E			2027E			2028E			2029E			2030E		
	Old	New	Diff %	Old	New	Diff %	Old	New	Diff %	Old	New	Diff %	Old	New	Diff %
Revenues	23,662	23,980	1%	39,107	91,262	133%	62,158	172,470	177%	91,060	253,524	178%	108,454	319,437	195%
GP	12,856	12,306	-4%	21,119	46,545	120%	33,256	87,099	162%	48,264	126,764	163%	56,941	159,721	181%
OP	6,451	6,424	0%	11,114	15,679	41%	18,188	30,896	70%	27,331	47,073	72%	33,252	60,787	83%
EBITDA	6,698	6,744	1%	11,376	16,004	41%	18,486	31,226	69%	27,646	47,407	71%	33,571	61,129	82%
Net income	6,142	6,179	1%	9,991	14,284	43%	15,992	27,265	70%	23,492	40,558	73%	27,885	51,100	83%
Margins															
GM	54.3%	51.3%		54.0%	51.0%		53.5%	50.5%		53.0%	50.0%		52.5%	50.0%	
OPM	27.3%	26.8%		28.4%	17.2%		29.3%	17.9%		30.0%	18.6%		30.7%	19.0%	
NM	26.0%	25.8%		25.5%	15.7%		25.7%	15.8%		25.8%	16.0%		25.7%	16.0%	

Source: Goldman Sachs Global Investment Research



Exhibit 2: Cambricon P&L

Rmb mn	2023	2024	2025	2026E	2027E	2028E	2029E	2030E	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26	3Q26E	4Q26E
Income statement																
Revenue	709	1,174	6,497	23,980	91,262	172,470	253,524	319,437	1,111	1,769	1,727	1,890	2,885	3,111	8,178	9,807
Gross profit	491	666	3,583	12,306	46,545	87,099	126,764	159,721	622	989	937	1,036	1,567	1,745	4,089	4,904
OP income	(867)	(803)	1,941	6,424	15,679	30,896	47,073	60,787	290	649	569	433	1,161	1,270	1,822	2,172
Net income	(845)	(452)	2,059	6,179	14,284	27,265	40,558	51,100	355	683	567	455	1,014	1,297	1,768	2,100
EBITDA	(617)	(632)	2,185	6,744	16,004	31,226	47,407	61,129	351	710	630	494	1,241	1,349	1,902	2,252
EPS (Rmb)	(2.05)	(1.09)	4.90	10.63	22.58	43.40	64.55	81.33	0.85	1.63	1.34	1.08	2.40	2.06	2.81	3.34
Ratios																
Opex ratio	191%	125%	25%	25%	34%	33%	31%	31%	30%	19%	21%	32%	14%	15%	28%	28%
Tax rate	0%	0%	0%	3%	10%	12%	14%	16%	0%	0%	0%	0%	0%	-1%	5%	5%
Margins																
Gross margin	69.2%	56.7%	55.2%	51.3%	51.0%	50.5%	50.0%	50.0%	56.0%	55.9%	54.2%	54.8%	54.3%	56.1%	50.0%	50.0%
Operating margin	-122.2%	-68.4%	29.9%	26.8%	17.2%	17.9%	18.6%	19.0%	26.1%	36.7%	32.9%	22.9%	40.3%	40.8%	22.3%	22.1%
Net margin	-119.1%	-38.5%	31.7%	25.8%	15.7%	15.8%	16.0%	16.0%	32.0%	38.6%	32.8%	24.1%	35.2%	41.7%	21.6%	21.4%
EBITDA margin	-189.1%	-61.5%	-618.4%	-212.7%	-371.8%	-42.3%	-457.7%	-307.2%	31.6%	40.1%	36.5%	26.2%	43.0%	43.4%	23.3%	23.0%
YoY																
Revenue	-3%	66%	453%	269%	281%	89%	47%	26%	4230%	4425%	1333%	91%	160%	76%	374%	419%
Gross profit	2%	36%	438%	243%	278%	87%	46%	26%	4108%	3727%	1417%	84%	152%	77%	337%	373%
OP income	na	na	na	231%	144%	97%	52%	29%	na	na	na	562%	301%	96%	220%	401%
Net income	na	na	na	200%	131%	91%	49%	26%	na	na	na	67%	185%	90%	212%	362%
EBITDA	na	na	na	209%	137%	95%	52%	29%	na	na	na	357%	253%	90%	202%	356%

Source: Company data, Goldman Sachs Global Investment Research

Valuation: We continue to use a discounted EV / EBITDA to derive our 12m target price and continue to use 2030E as the base year. Our target EV / EBITDA is based on peers' trading EV / EBITDA vs. forward year fundamentals (EBITDA YoY and EBITDA margin). After factoring in updated peer numbers, and Cambricon's updated EBITDA YoY (29% vs. 21% previously) and EBITDA margin (19% vs. 31% previously), our target EV / EBITDA is 27x (vs. 43x previously). We apply 27x to 2030E EBITDA and discount back to 2027E using a 12.7% COE (no change), and our new target price is Rmb1,841, implying 82x 2027E P/E, largely in line with Cambricon's avg. P/E of 84x since July 2024. Maintain Buy.

Exhibit 3: Cambricon vs. peers comparison

Company	Naura	Hygon	Piotech	Hua Hong	Empyrean
Ticker	002371.SZ	688041.SS	688072.SS	1347.HK	301269.SZ
Rating	Buy	NC	NC	Buy	Neutral
2027E EV/EBITDA	30	52	64	22	82
2027-28E EBITDA YoY	43%	44%	44%	39%	123%
2027-28E EBITDA margin	26%	34%	25%	36%	27%
Ratio	0.4	0.7	0.9	0.3	0.5
Peers avg.					0.6

NC: not covered, estimates from Bloomberg consensus; price as of 21 Aug, 2026

Source: Company data, Goldman Sachs Global Investment Research, Bloomberg

Exhibit 4: Cambricon discounted EV / EBITDA

Rmb m	2018	2019	2020	2021	2022	2023	2024	2025	2026E	2027E	2028E	2029E	2030E
Cambricon cloud chips (k units)	-	-	10	4	11	4	26	116	405	1,033	1,859	2,602	3,123
Cambricon cloud chips ASP (US\$)	-	-	1,288	1,506	1,914	2,913	6,252	7,776	8,239	12,358	12,976	13,625	14,306
Revenue	117	444	459	721	729	709	1,174	6,497	23,980	91,262	172,470	253,524	319,437
Revenue YoY	1392%	279%	3%	57%	1%	-3%	66%	453%	269%	281%	89%	47%	26%
GM	99.9%	68.2%	65.4%	62.4%	65.8%	69.2%	56.7%	55.2%	51.3%	51.0%	50.5%	50.0%	50.0%
GP	117	303	300	450	479	491	666	3,583	12,306	46,545	87,099	126,764	159,721
Opex ratio	249.1%	365.1%	213.7%	222.6%	261.4%	191.4%	125.1%	25.3%	24.5%	33.8%	32.6%	31.4%	31.0%
OP	(175)	(1,318)	(681)	(1,155)	(1,426)	(867)	(803)	1,941	6,424	15,679	30,896	47,073	60,787
OPM	-149.2%	-296.9%	-148.3%	-160.2%	-195.6%	-122.2%	-68.4%	29.9%	26.8%	17.2%	17.9%	18.6%	19.0%
Pretax profit	(41)	(1,179)	(435)	(824)	(1,323)	(875)	(456)	2,059	6,374	15,863	30,987	47,163	60,837
EBITDA	(159)	(1,268)	(560)	(965)	(1,141)	(617)	(632)	2,185	6,744	16,004	31,226	47,407	61,129
EBITDA YoY								209%	137%	95%	52%	29%	
Net profit	(41)	(1,179)	(435)	(825)	(1,257)	(845)	(452)	2,059	6,179	14,284	27,265	40,558	51,100
NP YoY								200%	131%	91%	49%	26%	

Target EV/EBITDA (sector EV/EBITDA)													27
Target EV/EBITDA x 2030 EBITDA													1,650,491
Enterprise value (Rmb, 2027E)									1,152,296				
Equity value (Rmb, 2027E)									1,164,218				
Value per share (Rmb, 2027E): Target Price									1,841				
Implied EV/Sales								48	13	7	5	4	
Implied P/E								188	82	43	29	23	

COE	12.7%
Beta	1.5
Risk-free rate	3.0%
Market risk premium	6.5%

Source: Company data, Goldman Sachs Global Investment Research, Bloomberg

Cambricon in six charts

Exhibit 5: Cambricon AI chips shipment and ASP




Exhibit 6: AI chips shipment and ASP: Cambricon vs peers

Price Target Risks and Methodology - Cambricon

Valuation: We are Buy rated on Cambricon. Our 12-month target price of Rmb1,841 is derived from a discounted EV/EBITDA analysis. We apply 27X EV/EBITDA to our 2030E EBITDA and discount it back to 2027E at a COE of 12.7%. Our 27X target EV/EBITDA

multiple is derived from China semis peers' correlation between the trading EV/EBITDA and forward year fundamentals (EBITDA YoY and EBITDA margin).

Key downside risks: 1) wafer supply restriction: Cambricon was added to US Entity list in Dec 2022; 2) slower-than-expected cloud chip development; 3) fiercer-than-expected competition in cloud chips.

Disclosure Appendix

Reg AC

We, Verena Jeng, Allen Chang and Yifan Hu, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

Contributing Authors: Verena Jeng Goldman Sachs (Asia) L.L.C., Allen Chang Goldman Sachs (Asia) L.L.C., Yifan Hu Goldman Sachs (Asia) L.L.C..

Unless otherwise stated, the individuals listed in the Contributing Authors disclosure of this report are analysts in Goldman Sachs' Global Investment Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

The rating(s) for Cambricon is/are relative to the other companies in its/their coverage universe: AAC, ACM Research, AMEC, ASMPT, AVC, AccoTest, Anji Micro, Asus, Auras, BOE, BYDE, Biren, CR Micro, CXMT, Cambricon, Chenbro, China Mobile (HK), China Telecom, China Tower Corp., China Unicom, Chinasoft Intl, Compal, Desay SV, E Ink, E-Town Semis, EHang, Empyrean, Eoptolink, FOCI, Fositek, Foxconn Industrial Internet, Gigabyte, Gigadevice, Glodon Co., HTC Corp., Hikvision, Hon Hai, Horizon Robotics, Hua Hong, Huace Navigation, Huaqin Co.(A), Huaqin Co.(H), Hwatsing, Iluvatar, InnoScience, Inspur, Insta360, Inventec, JCET, Kematek, King Slide, Kingdee, Kingsoft Office, LandMark, Largan, Lenovo, Lingyi, Luxshare (A), Luxshare (H), Maxscend, Meitu, MetaX, Mitac, Montage (A), Montage (H), NAURA, NSIG, Nexchip, OmniVision, Pegatron, Pony AI Inc. (ADR), Pony AI Inc. (H), Quanta, RoboTechnik, Ruijie Networks, SG Micro, SICC, SMIC (A), SMIC (H), SZS, Sangfor, SenseTime, Shengyi Tech, Shennan Circuits, StarPower, Sunny Optical, TFC Optical, Thundersoft, Tongyu Communication, Transsion, UMT, UNIS, VPEC, Vanchip, VeriSilicon, Victory Giant, WNC, WUS, WeRide, Wistron, Wiwynn, YJ Semitech, YOFC, Yonyou, ZTE (A), ZTE (H), iFlytek

Company-specific regulatory disclosures

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by Goldman Sachs Global Investment Research and referred to in this research.

There are no company-specific disclosures for: Cambricon (Rmb1,035.00)


Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe

	Rating Distribution				Investment Banking Relationships		
	Buy	Hold	Sell		Buy	Hold	Sell
Global	50%	34%	16%		65%	59%	43%

As of July 1, 2026, Goldman Sachs Global Investment Research had investment ratings on 3,104 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

Price target and rating history chart(s)



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.

Target price history table(s)

Cambricon (688256.SS)

Date of report Target price (Rmb) Closing price (Rmb)

04-May-26	2,406.00	1,140.91
31-Aug-25	2,104.00	1,001.67
24-Aug-25	1,835.00	834.36
21-Apr-25	1,223.00	466.44
20-Feb-25	607.80	415.11
23-Dec-24	538.00	435.40
29-Nov-24	468.50	376.51
21-Nov-24	411.90	345.18
02-Mar-24	115.00	114.09
08-Feb-24	101.50	77.45
12-Dec-23	98.50	103.36
03-Nov-23	86.50	73.17
05-Sep-23	88.70	96.98

Price targets shown in table(s) are unadjusted for corporate actions.

Regulatory disclosures

Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; registered market maker. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with a subject company, public appearances and trading in securities covered by the analysts.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at <https://www.gs.com/worldwide/brazil/area/gir/index.html>. Where applicable, the Brazil-registered analyst

primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst – SEBI Registration Number INH000001493, 10th Floor, Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai-400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details, a copy of the annual compliance audit report and other relevant information and disclosures can be found at this link: <https://www.goldmansachs.com/worldwide/india/research-analyst>. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for “professional investors” within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither “registered banks” nor “deposit takers” (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for “wholesale clients” (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: <https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html>. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom’s departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <https://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, and Investment Management Association of Japan. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock’s total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region’s Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts’ investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at <https://www.gs.com/research/hedge.html>.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs’ involvement in a transaction, and in certain other circumstances. **Early-Stage Biotech (ES).** An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company has neither a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil:

0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research within the European Economic Area.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<https://www.sipc.org>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, make a market or act as liquidity provider in, and buy or sell, any securities, derivatives, or other financial instruments referred to in this research (including any financial instruments issued by the companies referred to herein), unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <https://www.theocc.com/about/publications/character-risks.jsp> and https://www.goldmansachs.com/disclosures/cftc_fcm_disclosures. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <https://research.gs.com>.

Disclosure information is also available at <https://www.gs.com/research/hedge.html> or from Research Compliance, 200 West Street, New York, NY 10282.

© 2026 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any

such system.